EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

A multicenter phase II study of the intravenous administration of liposomal tretinoin in patients with acquired immunodeficiency syndrome-associated Kaposi's sarcoma



A multicenter phase II study of the intravenous administration of liposomal tretinoin in patients with acquired immunodeficiency syndrome-associated Kaposi's sarcoma



Cancer 95(12): 2555-2561



BACKGROUND. A multicenter trial was conducted to determine the efficacy and toxicity of escalating dosages of liposomal tretinoin (all-trans-retinoic acid) administered once or three times weekly in patients with acquired immunodeficiency syndrome (AIDS)-associated Kaposi sarcoma. METHODS. Seventy-six patients with acquired immunodeficiency syndrome (AIDS)-associated Kaposi sarcoma were randomized to receive the study drug either once (n = 30) or 3 times weekly (n = 46). The starting dosage was 60 mg/m2, which was escalated to 90 mg/m2 and then 120 mg/m2 if the drug was well tolerated (ltoreq Grade 2 toxicities (according to the Southwest Oncology Group toxicity scale)). Four weeks of therapy constituted 1 cycle; patients could receive up to 8 cycles and those who completed 8 cycles were given the option of receiving extended therapy. Clinical response was defined as complete response (CR), partial response (PR), or stable disease (SD). RESULTS. Efficacy was assessed after the completion of 3 treatment cycles; 28.9% of patients (22 of 76 patients) responded (no CRs, 1 PR, and 21 SDs). Among the patients receiving treatment 3 times weekly, 16 of 49 patients (32.7%) achieved a clinical response at the end of the third treatment cycle (no CRs, 1 PR, and 15 SDs). Concomitant or prior use of protease inhibitors did not appear to affect the patient's response to treatment (P = 0.183). CONCLUSIONS. Liposomal tretinoin is a new therapeutic agent that has been reported to have some clinical activity in patients with AIDS-associated Kaposi sarcoma. A three-times-per-week dosing schedule was noted to be more effective compared with a once-a-week schedule without any significant difference in toxicity reported.

(PDF emailed within 0-6 h: $19.90)

Accession: 010070938

Download citation: RISBibTeXText

PMID: 12467070

DOI: 10.1002/cncr.11009



Related references

Phase I study of human chorionic gonadotropin given subcutaneously to patients with acquired immunodeficiency syndrome-related mucocutaneous Kaposi's sarcoma. Journal of the National Cancer Institute 89(23): 1797-1802, 1997

Successful treatment with liposomal doxorubicin for widespread Kaposi's sarcoma and human herpesvirus-8 related severe hemophagocytic syndrome in a patient with acquired immunodeficiency syndrome. International Journal of Hematology 89(2): 195-200, 2009

A phase I trial of recombinant human interferon-gamma in patients with Kaposi's sarcoma and the acquired immunodeficiency syndrome (AIDS). Journal of Clinical Immunology 9(4): 351-361, 1989

Pilot study of cimetidine in the treatment of Kaposi's sarcoma in patients with acquired immunodeficiency syndrome. Journal of the National Cancer Institute 83(2): 139-141, 1991

Interferon and interferon inhibitor levels in patients infected with varicella zoster virus acquired immunodeficiency syndrome acquired immunodeficiency syndrome related complex or kaposi's sarcoma and in normal individuals. American Journal of Medicine 87(4): 405-407, 1989

Acquired immunodeficiency syndrome-related Kaposi's sarcoma of the axilla and breast after percutaneous intravenous catheter insertion. International Journal of Dermatology 44(7): 611-612, 2005

Inflammatory reactivation and angiogenicity of Kaposi's sarcoma-associated herpesvirus/HHV8: a missing link in the pathogenesis of acquired immunodeficiency syndrome-associated Kaposi's sarcoma. Blood 93(12): 4031-4033, 1999

Endemic kaposi's sarcoma vs. kaposi's sarcoma in acquired immunodeficiency syndrome a brief communication. Hiroshima Journal of Medical Sciences 34(3): 291-296, 1985

Kaposi's sarcoma of the penis in patients with acquired immunodeficiency syndrome. Journal of Urology 142(6): 1475-1477, 1989

Pharyngeal kaposi's sarcoma in patients with acquired immunodeficiency syndrome. AJR (American Journal of Roentgenology) 147(5): 919-922, 1986

Kaposi's sarcoma of the rectum in patients with the acquired immunodeficiency syndrome. American Journal of Surgery 160(6): 681-2; Discussion 682-3, 1990

A clinical study of Kaposi's sarcoma associated with the acquired immunodeficiency syndrome. Anales de Medicina Interna 9(12): 579-584, 1992

Cytogenetic study of Kaposi's sarcoma associated with acquired immunodeficiency syndrome. Archives of Pathology & Laboratory Medicine 112(8): 825-828, 1988

Kaposi's sarcoma of the head and neck in patients with acquired immunodeficiency syndrome. Otolaryngology--Head and Neck Surgery 111(5): 618-624, 1994